NCT06473285View on ClinicalTrials.gov

Effects of Esketamine on Consciousness-related Brain Network Characteristics in Patients With Prolonged Disorders of Consciousness

NARecruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Prolonged Disorders of Consciousness
Interventions
DRUG

Drug: Esketamine (Continuous infusion)

Continuous intravenous infusion of ketamine at a dose of 0.3mg/(kg · h). Collect resting state EEG and auditory event-related potential (ERP) before administration (baseline), 60 minutes after administration, 30 and 60 minutes after discontinuation.

Trial Locations (1)

100070

RECRUITING

Beijing Tiantan Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER